New drug targets Hard-to-Treat cancers with KRAS G12D mutation
NCT ID NCT06818812
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 22 times
Summary
This early-phase study tests an experimental drug called INCB186748 in 30 adults with advanced or metastatic solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and find the right dose. Researchers will also watch for side effects and see if tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Jefferson University Hospitals
Philadelphia, Pennsylvania, 19107, United States
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Sarah Cannon Research Institue At Healthone
Denver, Colorado, 80218, United States
-
Scri Oncology Partners
Nashville, Tennessee, 37203, United States
-
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland, 21287-7049, United States
-
UCLA Healthcare Hematology-Oncology
Santa Monica, California, 90404, United States
Conditions
Explore the condition pages connected to this study.